Glycosaminoglycans in the blood of hereditary multiple exostoses patients: Half reduction of heparan sulfate to chondroitin sulfate ratio and the possible diagnostic application

Glycobiology

Volumn 23, Issue 7, 2013, Pages 865-876

  Anower E Khuda, Md Ferdous ^a   Matsumoto, Kazu ^b   Habuchi, Hiroko ^a   Morita, Hiroyuki ^a   Yokochi, Takashi ^a   Shimizu, Katsuji ^b   Kimata, Koji ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

chondroitin sulfate; chondroitinase; heparan sulfate; heparinase; hereditary multiple exostoses

Indexed keywords

ALCOHOL; CHONDROITIN SULFATE; DISACCHARIDE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; N ACETYLGALACTOSAMINE 4 SULFATASE;

ARTICLE; BLOOD SAMPLING; ENZYME ANALYSIS; HEREDITARY MULTIPLE EXOSTOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MOLECULAR WEIGHT; PHENOTYPE; POLYMERIZATION; PRECIPITATION; PRIORITY JOURNAL;

CHONDROITIN SULFATE; CHONDROITINASE; HEPARAN SULFATE; HEPARINASE; HEREDITARY MULTIPLE EXOSTOSES;

ADULT; AGED; BLOOD CHEMICAL ANALYSIS; CHONDROITIN SULFATES; EXOSTOSES, MULTIPLE HEREDITARY; FEMALE; GLYCOSAMINOGLYCANS; HEPARITIN SULFATE; HUMANS; MALE; MIDDLE AGED; MUTATION; N-ACETYLGLUCOSAMINYLTRANSFERASES; PROSPECTIVE STUDIES;

EID: 84881104181     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwt024     Document Type: Article

References (61)

1. Adell K, Ogbonna G. 1990. Rapid purification of human DNA from whole blood for potential application in clinical chemistry laboratories. Clin Chem. 36/2:261-264.
2. Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH, Smith RD, Springer DL, Pounds JG. 2002. Toward a human blood serum proteome. Mol Cell Proteomics. 1:947-955.
3. Ahn J, Ludecke HJ, Lindow S, Horton WA, Lee B, Wagner MJ, Horsthemke B, Wells DE. 1995. Cloning of the putative tumor suppressor gene for hereditary multiple exostoses (EXT1). Nat Genet. 11:137-143.
4. Lewin B. 1994. Genes V. Oxford: Oxford University Press. p. 59-79.
5. Bernard MA, Houge DA, Cole WG, Sanford T, Snuggs MB, Montufar-solis D, Duke PJ, Carson DD, Scott A, Van Winkle WB, et al. 2000. Cytoskeletal abnormalities in chondrocytes with EXT1 and EXT2 mutations. J Bone Miner Res. 15:442-450.
6. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 68:729-777.
7. Cafolla A, D'Andrea G, Baldacci E, Margaglione M, Mazzucconi MG, Foa R. 2012. Hereditary protein C deficiency and thrombosis risk: Genotype and phenotype relation in a large Italian family. Eur J Haematol. 88:336-339.
8. Calatroni A, Vinci R, Ferlazzo AM. 1992. Characteristics of the interactions between acid glycosaminoglycans and proteins in normal human plasma as revealed by the behavior of the protein-polysaccharide complexes in ultrafiltration and chromatographic procedures. Clin Chim Acta. 206:167-180.
9. Chen CP, Chang SC, Yang WCV. 2007. High glucose alters proteoglycan expression and the glycosaminoglycan composition in placentas of women with gestational diabetes mellitus and in cultured trophoblasts. Placenta. 28:97-106.
10. Chiurco AA. 1970. Multiple exostoses of bone with fatal spinal cord compression; a report of a case and brief review of the literature. Neurology. 20:275-278.
11. Duffy PE, Fried M. 2003. Antibodies that inhibit plasmodium falciparum adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of newborns. Infect Immun. 71:6620-6623.
12. Esko JD, Kimata K, Lindahl U. 2009. Proteoglycans and sulfated glycosaminoglycans. In: Varki A, Cummings R, et al. editors. Essentials of Glycobiology. New York, NY: Cold Spring Harbor Laboratory Press. p. 229-248.
13. Esko JD, Zhang L. 1996. Influence of core protein sequence on glycosaminoglycan assembly. Curr Opin Struct Biol. 6:663-670.
14. Gill J, Chitnis CE, Sharma A. 2009. Structural insights into chondroitin sulfate A binding duffy-binding-like domains from plasmodium falciparum: Implications for intervention strategies against placental malaria. Malar J. 8:1-10.
15. Goldenberg NA, Manco-Johnson MJ. 2008. Protein C deficiency. Haemophilia. 14:1214-1221.
16. Hall CR, Cole WG, Haynes R, Hecht JT. 2002. Reevaluation of a genetic model for the development of exostosis in hereditary multiple exostosis. Am J Med Genet. 112:1-5.
17. Hata RI, Ohkawa SI, Nagai Y. 1978. Low-sulfated chondroitin sulfate in human blood and urine. Biochem Biophys Acta. 543:156-166.
18. Hecht JT, Hall CR, Snuggs M, Hayes E, Haynes R, Cole WG. 2002. Heparan sulfate abnormalities in exostosis growth plates. Bone. 31:199-204.
19. Hecht JT, Hayes E, Haynes R, Cole WG, Long RJ, Farach-Carson MC, Carson DD. 2005. Differentiation-induced loss of heparan sulfate in human exostosis derived chondrocytes. Differentiation. 73:212-221.
20. Higgins MK. 2008. The structure of a chondroitin sulfate binding domain important in placental malaria. J Biol Chem. 283:21842-21846.
21. Huang Y, Toyoda H, Toida T, Imanari T. 1995. Determination of chondroitin sulfates in human whole blood, plasma and blood cells by highperformance liquid chromatography. Biomed Chromatogr. 9:102-105.
22. Jennes I, Pedrini E, Zuntini M, Mordenti M, Balkassmi S, Asteggiano CG, Casey B, Bakker B, Sangiorgi L, Wuyts W. 2009. Multiple osteochondromas: Mutation update and description of the multiple osteochondromas mutation database (MOdb). Hum Mutat. 30:1620-1627.
23. Jones KB, Piombo V, Searby C, Kurriger G, Yang B, Grabellus F, Roughley PJ, Morcuende JA, Buckwalter JA, Capecchi MR, et al. 2010. A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc Natl Acad Sci USA. 107:2054-2059.
24. Komosinska-Vassev K, Olczyk K, Kozma EM, Olczyk P, Wisowski G, Winsz-Szczotka K. 2005. Alteration of glycosaminoglycan metabolism in the development of diabetic complications in relation to metabolic control. Clin Chem Lab Med. 43:924-929.
25. Lawrence R, Olson SK, Steele RE, Wang L, Warrior R, Cummings RD, Esko JD. 2008. Evolutionary differences in glycosaminoglycan fine structure detected by quantitative glycan reductive isotope labeling. J Biol Chem. 283:33674-33684.
26. Legeai-Mallet L, Munnich A, Maroteaux P, Le Merrer M. 1997. Incomplete penetrance and expressivity skewing in hereditary multiple exostoses. Clin Genet. 52:12-16.
27. Legeai-Mallet L, Rossi A, Benoist-Lasselin C, Piazza R, Mallet JF, Delezoide AL, Munnich A, Bonaventure J, Zylberberg L. 2000. EXT1 gene mutation induces chondrocyte cytoskeletal abnormalities and defective collagen expression in the exostoses. J Bone Miner Res. 15:1489-1500.
28. Lin X, Wei G, Shi Z, Dryer L, Esko JD, Wells DE, Matzuk MM. 2000. Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. Dev Biol. 224:299-311.
29. Lind T, Tufaro F, McCormick C, Lindahl U, Lidholt K. 1998. The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem. 273:26265-26268.
30. Lu H, Mcdowell LM, Studelska DR, Zhang L. 2010. Glycosaminoglycans in human and bovine serum: Detection of twenty-four heparan sulfate and chondroitin sulfate motifs including a novel sialic acidmodified chondroitin sulfate linkage hexasaccharide. Glycobiol Insights. 2:13-28.
31. Ly M, Leach FE, 3rd, Laremore TN, Toida T, Amster IJ, Linhardt RJ. 2011. The proteoglycan bikunin has a defined sequence. Nat Chem Biol. 7 (11):827-833.
32. Matsumoto K, Irie F, Mackem S, Yamaguchi Y. 2010. A mouse model of chondrocyte specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses. Proc Natl Acad Sci USA. 107:10932-10937.
33. McCormick C, Duncan G, Goutsos KT, Tufaro F. 2000. The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. Proc Natl Acad Sci USA. 97:668-673.
34. McCormick C, Leduc Y, Martindale D, Mattison K, Esford LE, Dyer AP, Tufaro F. 1998. The putative tumor suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet. 19:158-161.
35. Mulloy B, Hart GW, Stanley P. 2009. Structural analysis of glycans. In: Varki A, Cummings R, et al. editors. Essentials of Glycobiology. New York, NY: Cold Spring Harbor Laboratory Press. p. 661-678.
36. Murata K. 1974. Acidic glycosaminoglycans in human platelets and leukocytes: The isolation and enzymatic characterization of chondroitin 4-sulfate. Clin Chim Acta. 57:115-124.
37. Pedrini E, Jennes I, Tremosini M, Milanesi A, Mordenti M, Parra A, Sgariglia F, Zuntini M, Campanacci L, Fabbri N, et al. 2011. Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses: Identification of "Protective" and "Risk" factors. J Bone Jt Surg Am. 93-A:2294-2302.
38. Plaas AHK, West LA, Wong-Palms S, Nelson FRT. 1998. Glycosaminoglycan sulfation in human osteoarthritis. Disease-related alterations at the nonreducing termini of chondroitin and dermatan sulfate. J Biol Chem. 273:12642-12649.
39. Pohlenz J, Ahrens W, Hiort O. 2003. A new heterozygous mutation (L338N) in the human Gsα (GNAS1) gene as a cause for congenital hypothyroidism in Albright's hereditary osteodystrophy. Eur J Endocrinol. 148:463-468.
40. Presto J, Thuveson M, Carlsson P, Busse M, Wilen M, Eriksson I, Kusche-Gullberg M, Kjellen L. 2008. Heparan sulfate biosynthesis enzymes EXT1 and EXT2 affect NDST1 expression and heparan sulfate sulfation. Proc Natl Acad Sci USA. 105:4751-4756.
41. Saito A, Munakata H. 2007. Analysis of plasma proteins that bind to glycosaminoglycans. Biochem Biophys Acta. 1770:241-246.
42. Schmale GA, Conrad EU, Raskind WH. 1994. The natural history of hereditary multiple exostoses. J Bone Jt Surg Am. 76:986-992.
43. Senay C, Lind T, Muguruma K, Tone Y, Kitagawa H, Sugahara K, Lidholt K, Lindahl U, Kusche-Gullberg M. 2000. The EXT1/EXT2 tumor suppressors: Catalytic activities and role in heparan sulfate biosynthesis. EMBO Rep. 1:282-286.
44. Shapiro F, Simon S, Glimcher MJ. 1979. Hereditary multiple exostoses. J Bone Jt Surg Am. 61:815-824.
45. Solomon L. 1964. Hereditary multiple exostosis. Am J Hum Genet. 16:351-363.
46. Stickens D, Clines G, Burbee D, Ramos P, Thomas S, Hogue D, Hecht JT, Lovet M, Evans GA. 1996. The EXT2 multiple exostoses gene defines a family of putative tumor suppressor genes. Nat Genet. 14:25-32.
47. Stickens D, Zak BM, Rougier N, Esko JD, Werb Z. 2005. Mice deficient in Ext2 lack heparan sulfate and develop exostoses. Development. 132:5055-5068.
48. Toyoda H, Kinoshita-Toyoda A, Selleck SB. 2000. Structural analysis of glycosaminoglycans in Drosophila and Caenorhabditis elegans and demonstration that tout-velu, a Drosophila gene related to EXT tumor suppressors, affects Heparan Sulfate in Vivo. J Biol Chem. 275:2269-2275.
49. Vannucchi S, Fibbi G, Cella C, Del Rosso M, Cappelletti R, Chiarugi VP. 1980. Cell surface glycosaminoglycans in normal and leukemic leukocytes. Cell Differ. 9:71-81.
50. Varki A, Esko JD, Colley KJ. 2009. Cellular organization of glycosylation. In: Varki A, Cummings R, et al. editors. Essentials of Glycobiology. New York, NY: Cold Spring Harbor Laboratory Press. p. 37-46.
51. Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, Ferrone CR, Favoino E, Koya Y, Campoli MR, et al. 2010. CSPG4 in cancer: Multiple roles. Curr Mol Med. 10:419-429.
52. Wannarat Y, Lisheng Z, Matthias M, Yoneda M, Kida D, Kimata K. 2003. Molecular heterogeneity of the SHAP-hyaluronan complex. J Biol Chem. 278:32710-32718.
53. Wei G, Bai X, Gabb MMG, Bame KJ, Koshy TI, Spear PG, Esko JD. 2000. Location of the glucuronosyltransferase domain in the heparan sulfate copolymerase EXT1 by analysis of Chinese hamster ovary cell mutants. J Biol Chem. 275:27733-27740.
54. Wei W, Ninonuevo MR, Sharma A, Danan-Leon LM, Leary JA. 2011. A comprehensive compositional analysis of heparin/heparan sulfate-derived disaccharides from human serum. Anal Chem. 83:3703-3708.
55. Wicklund CL, Pauli RM, Johnston D, Hecht JT. 1995. Natural history study of hereditary multiple exostoses. Am J Med Genet. 55:43-46.
56. Wuyts W, Hul WV. 2000. Molecular basis of multiple exostoses: Mutations in the EXT1 and EXT2 genes. Hum Mutat. 15:220-227.
57. Yamada S, Busse M, Ueno M, Kelly OG, Skarnes WC, Sugahara K, Kusche-Gullberg M. 2004. Embryonic fibroblasts with a gene trap mutation in Ext1 produce short heparan sulfate chains. J Biol Chem. 279:32134-32141.
58. Zak BM, Crawford BE, Esko JD. 2002. Hereditary multiple exostoses and heparan sulfate polymerization. Biochim Biophys Acta. 1573:346-355.
59. Zak BM, Schuksz M, Koyama E, Mundy C, Wells DE, Yamaguchi Y, Pacifici M, Esko JD. 2011. Compound heterozygous loss of Ext1 and Ext2 is sufficient for formation of multiple exostoses in mouse ribs and long bones. Bone. 48:979-987.
60. Zhuo L, Hascall VC, Kimata K. 2004. Inter-alpha-trypsin inhibitor, a covalent protein-glycosaminoglycan-protein complex. J Biol Chem. 279:38079-38082.
61. Zhuo L, Salustri A, Kimata K. 2003. A physiological function of serum proteoglycan bikunin: The chondroitin sulfate moiety plays a central role. Glycoconj J. 19:241-247.